丽珠集团上半年净利12.81亿元，同比增长9.4%

Core Insights - Lijun Group reported a slight decline in revenue for the first half of 2025, with total revenue at 6.272 billion yuan, a year-on-year decrease of 0.17% [2] - The net profit attributable to shareholders increased by 9.4% year-on-year, reaching 1.281 billion yuan [2] Revenue Breakdown - The company's various business segments showed collaborative growth, contributing to a stable overall performance [2] - Key product segments such as digestion, mental neurology, reproduction, and traditional Chinese medicine experienced year-on-year revenue growth [2] - The raw materials and intermediates segment saw a slight revenue decline due to price fluctuations in cephalosporin raw materials in the domestic market [2] - The diagnostics reagents and equipment segment faced a minor revenue drop influenced by cyclical changes in respiratory products, following a high base in the first half of 2024 [2]